Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo‐controlled trial
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background Previous published studies assessed the efficacy of bupropion in smoking cessation only in North American populations of smokers. Results of therapeutic drug trials are not always directly applicable in other populations. Aims To confirm the efficacy of bupropion in smoking cessation in European smokers. Design A multi‐centre, randomized, double‐blind placebo‐controlled trial. Setting Seventy‐four smoking cessation out‐patient clinics in France. Participants The study included 509 smokers motivated to quit smoking. Intervention Subjects were randomized to either slow‐release bupropion 150 mg b.i.d. (B) or to placebo (Pl) in a 2 : 1 ratio, treated for 7 weeks, and followed‐up for 26 weeks. Measurements Main outcome measure: 6 months’ point prevalence abstinence, determined by self‐report and expired air carbon monoxide measurement. Secondary outcome measures: weeks 4–7 and weeks 4–26 continuous abstinence rates, craving, withdrawal symptoms, weight and cigarette consumption in smokers unable to quit. Adverse events were recorded systematically. Findings Six months’ point prevalence abstinence rates were 31% and 16%[odds ratio = 2.3, confidence interval (CI) 95%: 1.4–3.7] in the B and Pl groups, respectively. Continuous abstinence rates were 41% (B) and 21% (P) with OR = 2.5 (CI 95%: 1.6–3.9) for weeks 4–7, and 25% (B) and 13% (P) with OR = 2.2 (CI 95%: 1.3–3.6) for weeks 4–26, respectively. Craving decreased significantly more with B than with Pl during treatment period, but there was no difference for total withdrawal symptoms score. Abstinent subjects gained significantly less weight at week 7 with B than with Pl. Low level of nicotine dependence, high motivation, absence of smoking‐related disease, long duration of previous quit attempts, male gender, low level of current alcohol problems and living as a couple were predictive of successful cessation. With the exception of marital status, no interaction was observed between any of these predictive factors and the efficacy of bupropion. More of those who continued smoking in the B group than the P group reduced their consumption by at least 50%. Conclusions Sustained‐release bupropion is efficacious as an aid to smoking cessation in European smokers. No outcome predictors were identified that might indicate that certain subgroups of smokers would benefit more than others from treatment with bupropion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 5×
“These results in a European population are qualitatively similar to those observed in previous North American placebo-controlled trials with sustained-release bupropion (Hurt et al. 1997; Jorenby et al. 1999; Alhuwalia et al. 2002; Jorenby 2002), as well as in a pilot study with the standard formulation of bupropion (…”
BackgroundResultInfluentialAntidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
The Alcohol Use Disorders Identification Test (AUDIT): A review of recent research
Reinert, D. F., & Allen, J. P. (2002) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2002.tb02534.x · Cited by 1,143
Predictors of smoking cessation in a cohort of adult smokers followed for five years
Hymowitz, N., Cummings, K., Hyland, A., Lynn, W., Pechacek, T., & Hartwell, T. (1997) · Tobacco Control · doi:10.1136/tc.6.suppl_2.s57 · Cited by 593
Hays, J. T., Hurt, R. D., Rigotti, N. A., Niaura, R., Gonzales, D., Durcan, M. J., Sachs, D. P. L., Wolter, T. D., Buist, A. S., Johnston, J. A., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00011 · Cited by 343
Cigarette smoking and major depression
Covey, L. S., Glassman, A. H., & Stetner, F. (1998) · Journal of Addictive Diseases · doi:10.1300/j069v17n01_04 · Cited by 302 · cited 2×
“…smoker groups, with some having poorer outcome than others: for example, heavy smokers (Jackson et al. 1986; Ward et al. 1997), those with a history of depression (Glassman et al. 1988; Covey et al. 1998), African Americans (Fiore et al. 1989) and women (Jackson et al. 1986; Ward et al. 1997).”
BackgroundHayford, K. E., Patten, C. A., Rummans, T. A., Schroeder, D. R., Offord, K. P., Croghan, I. T., Glover, E. D., Sachs, D. P. L., & Hurt, R. D. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.174.2.173 · Cited by 264
Bupropion for Smoking Cessation
Dale, L. C., Glover, E. D., Sachs, D. P. L., Schroeder, D. R., Offord, K. P., Croghan, I. T., & Hurt, R. D. (2001) · Chest · doi:10.1378/chest.119.5.1357 · Cited by 177
Heavy Smokers, Smoking Cessation, and Clonidine: Results of a Double-blind, Randomized Trial
Glassman, A. H. (1988) · JAMA · doi:10.1001/jama.1988.03720190031026 · cited 2×
“…smoker groups, with some having poorer outcome than others: for example, heavy smokers (Jackson et al. 1986; Ward et al. 1997), those with a history of depression (Glassman et al. 1988; Covey et al. 1998), African Americans (Fiore et al. 1989) and women (Jackson et al. 1986; Ward et al. 1997).”
Background
Cited by
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub3 · Cited by 567
Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies: A Network Meta-Analysis
Mills, E. J., Thorlund, K., Eapen, S., Wu, P., & Prochaska, J. J. (2014) · Circulation · doi:10.1161/circulationaha.113.003961 · Cited by 408
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub4 · Cited by 348
Interventions for preventing weight gain after smoking cessation
Farley, A. C., Hajek, P., Lycett, D., & Aveyard, P. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006219.pub3 · Cited by 334
Metadata
- Authors
- Aubin, H. J., Lebargy, F., Berlin, I., Bidaut‐Mazel, C., Chemali‐Hudry, J., & Lagrue, G.
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2004-08-18
- Volume
- 99
- Issue
- 9
- Pages
- 1206-1218
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W2086542708
- Cited by
- 68
- References
- 9
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo‐controlled trial. https://app.cochat.ai/papers/10.1111/j.1360-0443.2004.00814.x
- The paper
- Aubin, H. J., Lebargy, F., Berlin, I., Bidaut‐Mazel, C., Chemali‐Hudry, J., & Lagrue, G. (2004). Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo‐controlled trial. Addiction. https://doi.org/10.1111/j.1360-0443.2004.00814.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.